CORE--BLOOD PRODUCTS

细胞处理核心将提供关键资源，绕过许多限制干细胞分离、分子特征、功能分析和基因改造进展的技术问题。这些限制中的主要限制是无法获得足够数量的纯化干细胞，这是进行实验和优化有效转导所需的体外条件所需的。该核心将通过提供三个具体功能来解决这一限制。(1)CORE将为SCOR研究人员提供大量纯化的干细胞，用于大型动物模型试验的体外研究和临床试验。利用FHCRC低温生物学实验室提供的仪器和专业知识，Core将为从人类和大型动物(如狗和灵长类动物)获得的成分提供临床级干细胞浓缩。(2)CORE将通过进行2色和3色流式细胞术检测以及定量的CFC和LTC-IC检测来表征浓缩和转导的干细胞群体。这些诊断服务将使SCOR研究人员能够对上述成分处理的结果进行质量控制，并确定各种干细胞/祖细胞隔间中基因转导的效率。(3)核心将实施一项捐赠者招募计划和一个低温保存标本储存库。已建立的方案允许通过分离从经G-CSF处理或未经处理的捐赠者中收集大量细胞，这将为涉及人类细胞的SCOR项目提供临床数量的细胞。同样，核心将收集和分发少量的人类骨髓。该资料库存储了来自正常捐赠者或已获得使用这些产品进行研究的减少患者的PBSC成分的储存骨髓。该资料库将作为SCOR调查人员获取特定细胞进行研究的原始材料。这种处理和分离大量细胞的能力将极大地加强和促进干细胞生物学领域的研究，并开发和测试用于治疗造血疾病的基因治疗方法的改进。

The Cell Processing Core will provide critical resources that will circumvent many of the technical problems that limit progress in the isolation, molecular characterization, functional analysis and genetic modification of stem cells. Primary among these limitations is an inability to obtain sufficient quantities for purified stem cells needed for experimentation and optimization of the ex-vivo conditions required for efficient transduction. This Core will address that limitation by providing three specific functions. (1) The Core will provide SCOR investigators with access to large quantities of purified stem cells for in vitro studies for large animal model testing, and for clinical trial usage. Taking advantage of the instrumentation and expertise available from within the FHCRC Cryobiology Laboratory, the Core will provide clinical-grade stem cell enrichment for components obtained from both human and large animals such as dogs and primates. (2) The Core will characterize enriched and transduced stem cell populations by performing 2 and 3 color flow cytometric determinations and quantitative CFC and LTC-IC assay. These diagnostic services will provide SCOR investigators with the ability to quality control results from the component processing described above, and to determine efficiencies of gene transduction in the various stem/progenitor cell compartments. (3) The Core will operate a donor recruitment program and a Repository of Cryopreserved Specimens. Established protocols permit collection by apheresis of large quantities of cells from G-CSF-treated or untreated donors, which will provide clinical quantities of cells for the SCOR projects involving human cells. Similarly, the Core will collect and distribute small quantities of human bone marrow. The Repository contains stored marrow of PBSC components from normal donors or decreased patients where permission to use these products for research has been obtained. This Repository will serve as source material for SCOR investigators to obtain specific cells for their research studies. This ability to process and isolate large numbers of cells will greatly enhance and facilitate research studies in the areas of stem cell biology, and to develop and test improvements to gene therapy approaches for the treatment of hematopoietic disorders.